IDWeek 2012: HIV

IDWeek 2012: HIV

Telaprevir Exposure Comparable With or Without Concomitant Antiretroviral Therapy

The pharmacokinetics across combinations of concomitant telaprevir and efavirenz or atazanavir/ritonavir-based regiments in hepatitis C (HCV)/HIV co-infected patients were comparable and consistent with those observed historically in HCV mono-infected patients, according to Varun Garg, PhD, from Vertex Pharmaceuticals, Inc., Cambridge, MA, at IDWeek 2012.